On 11/16/2009, Omnimmune Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Omnimmune Holdings Inc. reported earnings results for the second quarter ended June 30, 2009. For the quarter, the company's net loss for the quarter was $458,984, up from $3.02 million for the same quarter the previous year 2008.

Omnimmune Holdings, Inc. plans to raise funds. The firm said in Form 10-Q filed with Securities and Exchange Commission (SEC), “Management is seeking to raise additional money through private debt and equity offerings to enable us to satisfy our cash requirements in the coming months and beyond and to fund ongoing research and development activities. We are not self-supporting through internally generated capital, and rely exclusively on our continued ability to raise additional funds through private or public debt or equity financings to meet our ongoing cash needs. We will require substantial additional funding in order to meet our obligations to our licensors, continue our research and product development programs, including preclinical testing and clinical trials of our product candidates, and meet ongoing operating expenses. We expect to continue to incur substantial losses through at least the next several years and may incur losses in subsequent periods. The amount and timing of our future losses are highly uncertain. Our ability to achieve and thereafter sustain profitability will be dependent upon, among other things, successfully developing, commercializing and obtaining regulatory approval or clearances for our technologies and products resulting from these technologies, which will require substantial additional funding, the availability of which is uncertain. A material shortage of capital will require us to take drastic steps such as reducing our levels of operations, disposing of selected assets, curtailing our development efforts or seeking an acquisition partner. If cash is insufficient, we may not be able to continue operations.”